![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 43, 41032-41037, October 25, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,

From the
Division of Neurobiology, Department of
Psychiatry and ** Department of Biochemistry and Biophysics,
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, the § Donner Laboratory, Lawrence Berkeley National
Laboratory, Berkeley, California 94720, the ¶ Department of
Molecular and Cell Biology, University of California, Berkeley,
California 94720, and the
Department of Chemistry, University of
Massachusetts at Dartmouth, Dartmouth, Massachusetts 02747
Received for publication, June 12, 2002, and in revised form, August 7, 2002
| |
ABSTRACT |
|---|
|
|
|---|
The pathology of Huntington's disease is
characterized by neuronal degeneration and inclusions containing
N-terminal fragments of mutant huntingtin (htt). To study htt
aggregation, we examined purified htt fragments in vitro,
finding globular and protofibrillar intermediates participating in the
genesis of mature fibrils. These intermediates were high in
Huntington's disease
(HD)1 is an inherited,
neurodegenerative disorder resulting from an expanded polyglutamine
(poly(Q)) region in the N terminus of huntingtin (htt) (1-4).
Individuals affected with HD have a poly(Q) stretch of 36 or more
glutamines and an age of disease onset inversely correlated with the
length of the expanded poly(Q) region (5). HD post-mortem brain
examination reveals intranuclear and cytoplasmic neuronal inclusions
and other deposits, consisting of fibrillar huntingtin aggregates
(6-9). However, the presence of these large inclusions does not
correlate well with neuronal death (10-14), suggesting that they may
not be the toxic species. In vitro, expanded htt forms
fibrillar aggregates with morphological and biophysical properties
similar to those formed by amyloid Plasmid Construction--
Plasmids encoding huntingtin exon 1 (htt exon1) proteins with either 16 or 44 consecutive glutamine
residues were prepared using a multistep PCR-based and synthetic DNA
approach (18). The 5' and 3' regions of htt exon1 DNA were individually
cloned into the Bluescript vector (Stratagene; 5', SalI and
XbaI sites; XbaI and NotI sites). The
3' htt exon1 cDNA fragment was then inserted into the 5' vector
(XbaI and NotI sites) to yield a modified httt
exon1 cDNA with a 42-base pair linker between the 5' and 3'
regions. To generate the 16Q htt exon1 construct, an oligonucleotide comprised of a mixed CAG/CAA sequence and encoding for 14 glutamine residues was inserted into the modified htt exon1 cDNA using the BseRI and BsgI restriction sites flanking the
synthetic linker. To prepare the 44Q htt exon1 construct, two
additional rounds of PCR were carried out to add a total of 30 CAG/CAA
codons to the repeat region. The CAG/CAA oligonucleotide was then
inserted into this modified vector to yield the final 44Q htt exon1
construct. Finally, both 16Q and 44Q inserts were sublconed into a
modified pMAL vector (New England Biolabs) using SalI and
NotI restriction sites to allow for expression as MBP fusion proteins.
Expression and Purification of Recombinant Proteins--
MBP-htt
exon1 fusion proteins were expressed in Escherichia coli,
grown to an OD600 of 0.6-0.8, induced with 0.3 mM (final concentration)
isopropyl- Antibodies--
A goat polyclonal antibody was prepared against
the N-terminal htt exon-1 fragment as described previously (19).
Anti-MBP was purchased from New England Biolabs and expanded
polyglutamine selective monoclonal antibody 1C2 was obtained from
Chemicon International.
Preparation of htt Exon1 for Fibrilization Studies--
Purified
fusion proteins were dialyzed against 50 mM Tris-Cl, pH
8.0, 100 mM NaCl, 5 mM CaCl2, and
10% glycerol. Final protein concentrations were estimated using
Bio-Rad protein assay with bovine serum albumin as a standard. To
remove the MBP affinity tag and induce aggregation of htt exon1-44Q,
dialyzed fusion protein (0.25 mg/ml) was digested with factor Xa
protease (Novagen; 1 µg of enzyme:25 µg of protein) at room
temperature. At various time points, aliquots were removed and mixed
with SDS sample buffer to terminate the cleavage reaction. Digest
reactions were analyzed by SDS-PAGE (4-15%) and Western blotting
using anti-htt exon1, anti-MBP, or 1C2 antibodies.
TEM--
MBP-htt digest reactions were carried out as described
above. For each time point analyzed, a 5-µl aliquot was removed and flash frozen in liquid N2. Prior to TEM analysis, freshly
thawed samples were applied to a carbon-coated copper grid and
negatively stained with 2% uranyl acetate. TEM imaging was carried out
using a Zeiss-EM10 equipped with a Gantan CCD camera.
FTIR Spectroscopy--
A Nicolet model 8210 FTIR spectrometer
equipped with a zinc selenide attenuated total reflectance accessory
and deuterated triglycerine sulfate (DTGS) detector was used for
spectral recordings at room temperature. The spectrometer was purged
with liquid nitrogen for 4 h before recording spectra. For each
spectrum, a 256-scan interferogram was collected at a resolution of 4 cm AFM--
Prior to analysis, a 5-µl aliquot of digested 44Q
protein was deposited onto freshly cleaved ruby mica (Mica, New York)
and allowed to adsorb for 30 s. The sample was washed with double distilled water, dried with nitrogen gas, and imaged in air with a
Nanoscope III microscope (Digital Instruments, Inc., Santa Barbara, CA)
operating in tapping mode as described previously (21). Images were
flattened with a first-order or second-order fit using Digital
Instruments software.
Recombinant htt Expression and Purification--
For these
studies, we prepared MBP-tagged htt exon1 fusion proteins with a normal
length (16Q) and a pathological length (44Q) poly(Q) region (Fig.
1A). A His6
tag was engineered at the C terminus of the fragment to allow isolation
of full-length exon 1 protein. SDS-PAGE followed by Coomassie staining
confirmed that the recombinant htt exon1 fusion proteins were >99%
pure following the second chromatography step (Fig. 1B,
left panel, lane 2). Western blot analysis
demonstrated that both normal length and pathological length htt exon1
proteins were recognized by an anti-huntingtin antibody (Fig.
1B, middle panel). However, only the htt
exon1-44Q protein was immunoreactive with 1C2 (Fig. 1B,
right panel), an antibody previously shown to selectively
recognize expanded poly(Q) tracts.
A Conformational Change in 44Q Monomer following Removal of MBP
Affinity Tag--
Previous studies have shown that following removal
of the N-terminal glutathione S-transferase tag, a htt exon1
fragment with an expanded poly(Q) region aggregates in a time- and
poly(Q) length-dependent manner (16). MBP-htt exon1 fusion
proteins were treated with factor Xa to remove the affinity tag and
induce expanded htt aggregation. The cleavage reaction was monitored by
Western blotting as shown in Fig. 1C. Analysis of the
digests with an anti-htt exon1 antibody showed that the htt 44Q protein
formed high molecular weight SDS-insoluble aggregates at later time
points in the cleavage reaction while the 16Q protein did not. These
observations are consistent with previous studies and confirm that
expanded but not normal length poly(Q), in the context of htt exon1,
aggregates following removal of an affinity tag. Interestingly,
reactivity to 1C2 was eliminated after MBP cleavage, even though the
cleaved htt protein is still recognized by an anti-htt antibody. This
change in immunoreactivity is unaffected by boiling in SDS and suggests
that a structural change in the 44Q monomer takes place following MBP removal.
Expanded htt Exon1 Forms Oligomeric Intermediates with a Coincident
Increase in Congo Red Prevents the Formation of htt Fibers, Leading to
Accumulation of Protofibrils--
Previous work has demonstrated that
Congo Red (CR), a dye used to assay for amyloid fibers, is also an
inhibitor of poly(Q)-mediated htt fibrilization (24). To determine the
effect of CR on the fibrilization of htt exon1-44Q, we treated the
purified protein with increasing concentrations of CR 30 min after
addition of factor Xa protease. Aliquots were removed at 4, 8, and
24 h, subjected to SDS-PAGE, and visualized by Coomassie staining
(Fig. 3A). Monomeric htt exon1
44Q was visible in all samples 4 and 8 h after the addition of
enzyme. After overnight incubation with 2.5 and 10 µM CR,
monomeric 44Q protein was visible even after an overnight incubation
with factor Xa, demonstrating that SDS-insoluble htt fibers were not formed under these conditions. These observations support previous data
that CR blocks poly(Q)-mediated fibrilization (24). In contrast, no
monomeric htt was detected in the control or 0.25 µM CR
conditions. By this time, all monomeric 44Q protein had presumably been
incorporated into SDS-insoluble fibers and remained at the origin of
electrophoresis (data not shown).
To visualize these effects at a morphological level, we imaged
CR-treated 44Q samples by TEM (Fig. 3, B and C).
Large fiber bundles were visible in the control sample (Fig.
3B). In contrast, numerous small individual htt fibrils were
visible in the CR-treated sample (Fig. 3C). Based on
SDS-PAGE analysis, these fibrils were not resistant to SDS
denaturation. Moreover, the individual fibrils were thinner than those
making up the fiber bundle, with a diameter of 4-5 nm, compared with
10-11 nm for the control. Upon closer inspection of the control
sample, we observed that at the ends of some fiber bundles were small
fibrils 4-5 nm in diameter. These 4-5-nm fibrils may represent
incomplete growth at the end of the fiber bundle. A possible
explanation for these observations is that fiber assembly is preceded
by the formation of smaller fibrils or SDS-sensitive protofibrils.
AFM Analysis of htt Fibrilization--
To further investigate the
poly(Q)-mediated htt fiber assembly pathway, we carried out AFM
analysis of MBP-htt exon1-44Q before and after removal of the affinity
tag. Before MBP cleavage, the fusion protein appeared by AFM as a
globular feature with a height of 1.2 nm, corresponding to the MBP
affinity tag, and a "tail" feature likely to represent the htt
exon1 fragment (Fig. 4A,
arrows). After an overnight incubation with factor Xa, large
fiber bundles were visible by AFM (Fig. 4B). These were not
observed for the htt exon1-16Q fragment, consistent with previous
findings that a poly(Q) tract of 16Q does not form amyloid fibers in
the context of the htt exon1 fragment. Individual fibers with a height
of 10-11 nm were visible at the ends of the fiber bundle, some of which displayed a segmented "beads on a string" morphology (Fig. 4B, inset, arrowheads). Upon careful
inspection of the close-up images, we observed thinner fibrils at some
of the bundle ends with a height of 4-5 nm (Fig. 4B,
inset, arrows). These height data are consistent
with the data observed for protofibrils and fibers visible by TEM
and strongly suggest that the htt exon1-44Q fibers observed by both
TEM and AFM are the same. Thus, the 4-5-nm globular features visible
early in the TEM cleavage reaction are likely protofibrillar subunits
and may represent oligomeric intermediates in the fibrilization
pathway.
A possible model, based on the current data, is shown in Fig.
5. Before removal of the affinity tag,
htt exon1 is soluble with an unstructured poly(Q) region. These
observations are consistent with previous structural studies suggesting
that poly(Q) is unstructured in solution (25-27). After removal of the
affinity tag, the expanded htt construct begins to adopt
-structure. Furthermore, Congo Red, a dye that stains amyloid
fibrils, prevented the assembly of mutant htt into mature fibrils, but
not the formation of protofibrils. Other proteins capable of forming
ordered aggregates, such as amyloid
and
-synuclein, form similar
intermediates, suggesting that the mechanisms of mutant htt aggregation
and possibly htt toxicity may overlap with other neurodegenerative disorders.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(A
) peptide (15). The
aggregation threshold in vitro mimics the glutamine length
threshold for the disease phenotype (16), suggesting that an abnormal
conformation of expanded htt plays a role in disease pathogenesis.
Recently, Thompson and colleagues (17) have designed polypeptides that
bind mutant htt, suppress aggregation in vivo, and reduce
pathology in both cell and animal models of poly(Q) disease. It is
possible that the pathway from soluble htt to fibrillar aggregate is a
multistep process, with the toxic species formed before the mature
fiber. To better understand this pathway, we have characterized the
morphological and structural features of poly(Q)-mediated htt
fibrilization using biochemical and biophysical techniques, including
SDS-PAGE, transmission electron microscopy (TEM), Fourier transform
infrared (FTIR) spectroscopy, and atomic force microscopy (AFM).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-D-thiogalactopyranoside (Calbiochem) for 2 h at 28 °C, and harvested by centrifugation for 15 min at 5,000 rpm. Cell pellets were resuspended in lysis buffer
(phosphate-buffered saline (PBS), pH 7.4, supplemented with 10 mM methionine, 2 mM EDTA, 5 mM
dithiothreitol, 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride (ICN Biochemicals), and Complete protease inhibitor mixture (Roche Molecular Biochemicals)), lysed by French pressure, and clarified by centrifugation at 13,000 rpm for 15 min. MBP fusion proteins were purified by incubation of the lysate supernatant with
amylose resin (New England Biolabs) in PBS, pH 7.4, for 30 min at
4 °C. Following several washes, MBP fusion proteins were eluted with
PBS supplemented with 10 mM maltose and further purified by
nickel chelate chromatography. Purified fusion proteins were analyzed
by SDS-PAGE and visualized by Coomassie staining.
1. For each reading, the single beam spectrum of the
buffer and protein solutions were divided by the background single beam
spectrum, before conversion to absorbance spectra. The final protein
spectra were obtained by subtraction of the buffer spectra and smoothed using a 7-point Savitsky-Golay algorithm. For all protein spectra, the
area of amide I region (1,600-1,700 cm
1) was normalized
to one. To compare secondary structural changes in different samples, a
second derivative calculation was performed using Grams/386 software
(Galactic Industries Corp.) as described previously (20).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (49K):
[in a new window]
Fig. 1.
A conformational change in htt exon1-44Q
following removal of an N-terminal MBP affinity tag. A,
schematic of MBP-htt exon1 recombinant proteins. A factor Xa cleavage
site is located between the MBP and htt exon1 domains. MBP is not drawn
to scale. B, SDS-PAGE analysis of MBP-htt exon1 following
bacterial expression and purification. Left panel,
purified fusion protein following amylose (1) and nickel (2) affinity
chromatography. Middle and right panels, Western blots using
anti-htt exon1 or 1C2 antibody. While both normal and expanded htt
exon1 fusion proteins are recognized by a htt-specific polyclonal
antibody, only the expanded fusion protein is immunoreactive with
monoclonal 1C2 antibody. C, Western blot analysis of MBP-htt
cleavage reaction (see "Experimental Procedures"). Digested
proteins were resolved by SDS-PAGE and visualized by Western blotting
using the indicated antibodies and a chemiluminescence detection system
(Renaissance enhanced luminol reagent). The antibody to MBP
demonstrates that proteolytic cleavage is complete. MBP-cleaved htt
exon1-44Q is recognized by a htt antibody. However, 1C2
immunoreactivity is lost following cleavage of the fusion protein. htt
aggregates at the top of the gel (arrow) are also recognized
by anti-htt but not by 1C2.
-Structure--
To assess morphological and structural
changes in the expanded poly(Q) region of htt exon1, we monitored the
MBP cleavage reaction of 44Q by TEM and FTIR spectroscopy (Fig.
2). As early as 30 min following addition
of protease, small globular assemblies with a diameter of 4-5 nm were
visible by TEM (not shown). These globular features increase in number
at longer incubation times of 2 and 3 h (Fig. 2, B and
C, respectively). At later time points between 4 and 6 h (Fig. 2, D-F), amyloid-like fibers were visible and
co-exist with the spherical assemblies. Interestingly, the number of
globular features decreased with a coincident increase in fibers. By
7 h post-MBP cleavage (Fig. 2G), only fibers were visible. Neither globular assemblies nor fibers were observed in a
control sample not treated with factor Xa (Fig. 2A). FTIR analysis of the cleavage reaction products revealed no evidence of the
-structure within 44Q in the 1,620-1,640-cm
1 region
(22, 23) at time 0 (Fig. 2I). However, a large increase in
the 1,620-cm
1 band, likely representing intermolecular
-structure (23), was observed 7 h following addition of enzyme.
This
-structure coincides with the assembly of htt fibers. At
earlier time points when there were exclusively or predominantly
oligomers (2 and 3.5 h, respectively; Fig. 2J), two
distinct IR bands were observed in the
-region (1,620-1,640
cm
1). These peaks may arise from an increase in
-sheet
and or
-turn structure (23), suggesting that at a time coinciding
with the appearance of globular oligomers, 44Q adopts a
-structure,
which may differ from that of the fibers.

View larger version (74K):
[in a new window]
Fig. 2.
Evidence for a morphological and structural
intermediate in poly(Q)-mediated htt fibrilization.
A-H, time course of factor Xa cleavage reaction as
monitored by TEM. MBP-htt exon1 44Q prior to addition of enzyme
(control) is shown in A. Distinct globular features likely
to represent htt oligomers are visible after a 30-min incubation with
enzyme (not shown) and become abundant at 2 h (B) and
3 h (C) post-MBP cleavage. The smallest particles
(arrowheads) are 4-5 nm in diameter. Larger particles are
also observed and may represent aggregates of small particles. At
4 h, fibers (arrows) begin to form. Oligomers and
fibers co-exist at 4, 5 (E), and 6 (F) h. By 7 and 8 h (G, H) only fibers are present. The
fibers appear to take on a more uniform morphology and can be seen
bundled together. Bars, 200 nm. I and
J, second derivative FTIR spectra of factor X-treated
MBP-htt exon1-44Q fusion protein. Fiber formation at 7 h
(I) is accompanied by a large increase in
-sheet
structure (1,620-cm
1 band, likely resulting from
intermolecular
-sheet (23)). A change in poly(Q) structure is also
observed at 2 and 3.5 h (J), with the appearance of two
distinct IR bands in the 1,620-1640-cm
1 region
(indicated by large arrow and resulting from
-sheet
and/or
-turn) (23). This change coincides with the appearance of htt
oligomers, as shown in C.

View larger version (81K):
[in a new window]
Fig. 3.
Congo Red prevents later, but not earlier,
stages of htt fibrilization. A, SDS-PAGE analysis of
CR inhibition experiment. MBP-htt exon1-44Q was treated with either
PBS or with CR 30 min after addition of factor Xa. Aliquots were
removed at 4, 8, and 24 h following addition of enzyme and mixed
with an equal volume of SDS sample buffer. Digested fusion proteins
were visualized by Coomassie staining. Protein bands represent the
following: 70 kDa, MBP-htt-exon1-44Q; 43 kDa, MBP; 28 kDa, htt-exon1.
For both the control and 0.25 µM CR samples, monomeric
htt exon1 is assembled into larger fibers and is no longer detected at
24 h. In contrast, monomeric htt protein is clearly visible in
samples treated with higher concentrations of CR. A concentration of 10 µM CR was used for subsequent TEM experiments.
B and C, TEM images of MBP-htt exon1-44Q after
overnight digestion with factor Xa in the absence (B) or
presence (C) of 10 µM CR. While fibers with a
diameter of 10-11 nm were observed in the control sample
(B), only smaller fibrils (arrows) 4-5 nm in
diameter were present in the CR-treated sample (C). The
smaller fibrils were only observed in the control sample at some ends
of the fiber bundle and may represent subunits of larger fibers.
Bars, 200 nm.

View larger version (69K):
[in a new window]
Fig. 4.
AFM analysis of htt fibers provides further
evidence for an oligomer-protofibril-fiber pathway of assembly.
A and B, prior to addition of factor Xa,
the fusion protein appears as a small, globular feature (MBP;
height = 1.2 nm) with an extended tail (arrows),
likely to represent htt exon1-44Q (400 nm scan size) (A).
Pictured in B is MBP-htt exon1-44Q following an overnight
incubation with enzyme. Two large fiber bundles are shown (2 µM scan size). Inset, AFM surface plot
depicting end of fiber bundle (200-500 nm scan size). Individual
fibers (arrowheads) have a height of 10-11 nm and display a
segmented morphology. At the end of some fibers were thinner fibrils
(arrows) with a height of 4-5 nm.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-structure
via conformational changes in the expanded poly(Q) and forms globular
assemblies likely to be intermediates in the fibrilization pathway.
Over time, the globular oligomers can associate linearly to form single
protofibrils. These protofibrils are not visible as isolated entities,
unless Congo Red is present to prevent their association. Importantly, the protofibrils are SDS-soluble, unlike mature htt fibers. Mature fiber formation may result from the association or concurrent growth of
two protofibrils or by addition of oligomers to a single protofibril;
our data cannot distinguish between these possibilities.

View larger version (32K):
[in a new window]
Fig. 5.
Schematic illustration of hypothetical
pathway for htt fibrilization following factor Xa-induced cleavage of
MBP-htt exon1-44Q. Following MBP cleavage, htt 44Q
monomers are released from MBP and undergo a conformational change. htt
exon1 monomers then associate to form globular assemblies (distinct
from MBP) with an average size of 4-5 nm. These htt oligomers can
associate to form protofibrils with heights of 4-5 nm by AFM and 5 nm
by electron microscopy. The final fiber has a diameter of 10-11
nm and is suggested to consist of two protofibrils. The transition from
single protofibril to fiber is blocked by Congo Red.
In the present studies, we show by electron microscopy and AFM
that expanded poly(Q) in the context of htt forms globular and
protofibrillar species. Such observations are reminiscent of previous
studies on other amyloidogenic proteins such as A
,
-synuclein,
and yeast (prion) Sup35 NM peptide (28-30). Morphological characteristics of these species are remarkably similar despite the
variation in amino acid composition and molecular size among the
different proteins. Recently, Wetzel and colleagues (31) have generated
two monoclonal antibodies that recognize fibrillar A
as well as
poly(Q) and other amyloid-like fibers. Taken together, these data
suggest that similar structures are formed upon conversion from the
normal to the mutant state and are likely to form by similar
mechanisms. Globular oligomers may represent early prefibrillar intermediates of fibrilization. By FTIR spectroscopy, we detected the
appearance of
-structure that coincides with the appearance of
globular oligomers, demonstrating that htt adopts secondary structure
early in the fibrilization pathway. Congo Red, a dye commonly used to
assay for amyloid fiber formation, prevented the assembly of mature htt
fibers, possibly by binding to the
-structure of the protofibril.
Studies of both A
and
-synuclein toxicity have suggested that
globules and/or protofibrils may be more toxic than mature fibers (32)
and that stabilization of protofibrillar intermediates may promote
disease pathogenesis (33). Recent experiments show that oligomers or
other prefibrillar aggregation intermediates are toxic in several
models (34, 35). Regardless of the toxic species, there is evidence
that structural changes take place before the appearance of mature
fibers and that a strong correlation exists between these alterations
and neurotoxicity. Based on the similarities between htt fibrilization
and that of other amyloid-forming proteins, we propose that HD toxicity
is also governed by such structural alterations. Characterization of
these changes may allow for the rational design of therapeutics at
multiple steps in htt fibrilization and, by analogy, for other
neurodegenerative diseases.
| |
ACKNOWLEDGEMENTS |
|---|
We thank W. Xiao for assistance with initial TEM experiments, L. Gonzalez and D. Borchelt for critical reading of the manuscript, M. Peters for the huntingtin antibody and assistance with htt construct design, B. R. Singh for use of the FTIR spectrometer, and H.-P. Moore for use of laboratory equipment.
| |
FOOTNOTES |
|---|
* This work was supported by National Institute of Neurological Disorders and Stroke Grant 6375, the Hereditary Disease Foundation Cure Huntington's Disease Initiative, the Huntington's Disease Society of America Coalition for the Cure (to C. A. R. and M. A. P.), and National Institutes of Health Grant GM40633 (to H. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Division of
Neurobiology, Dept. of Psychiatry, Johns University School of Medicine, 615 Ross Research Bldg., 720 Rutland Ave., Baltimore, MD 21205. Tel.:
410-614-0011; Fax: 410-614-0013; E-mail: caross@jhu.edu.
Published, JBC Papers in Press, August 8, 2002, DOI 10.1074/jbc.M205809200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
HD, Huntington's
disease;
htt, huntingtin;
A
, amyloid
;
poly(Q), polyglutamine;
TEM, transmission electron microscopy;
FTIR spectroscopy, Fourier
transform infrared spectroscopy;
AFM, atomic force microscopy;
MBP, maltose-binding protein;
CR, Congo Red;
PBS, phosphate-buffered
saline.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Gusella, J. F., and MacDonald, M. M. E. (2000) Nat. Rev. Neurosci. 1, 109-115[Medline] [Order article via Infotrieve] |
| 2. | Paulson, H. (2000) Brain Pathol. 10, 293-299[Medline] [Order article via Infotrieve] |
| 3. | Zoghbi, H. Y., and Orr, H. T. (2000) Annu. Rev. Neurosci. 23, 217-247[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Ross, C. A., Margolis, R. L., Rosenblatt, N. G., Becher, M. W., and Aylward, E. (1997) Mol. Med. 76, 305-338 |
| 5. | Duyao, M., Ambrose, C., Myers, R., Novelletto, A., Perischetti, F., Frontali, M., Folstein, S., Ross, C. A., Franz, M., Abbott, M., Gray, J., Conneally, P., Young, A., Penney, J., Hollingsworth, Z., et al.. (1993) Nat. Genet. 4, 387-392[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Becher, M. W., Kotzuk, J. A., Sharp, A. H., Davies, S. W., Bates, G. P., Price, D. L., and Ross, C. A. (1998) Neurobiol. Dis. 4, 387-397[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., and Bates, G. P. (1997) Cell 90, 537-548[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Difiglia, M.,
Sapp, E.,
Chase, K. O.,
Davies, S. W.,
Bates, G. P.,
Vonsattel, J. P.,
and Aronin, N.
(1997)
Science
277,
1990-1993 |
| 9. | Rubinsztein, D. C., Leggo, J., Coles, R., Almqvist, E., Biancalana, V., Cassiman, J. J., Chotai, K., Connarty, M., Crauford, D., Curtis, A., Curtis, D., Davidson, M. J., Differ, A. M., Dode, C., Dodge, A., et al.. (1996) Am. J. Hum. Genet. 59, 16-22[Medline] [Order article via Infotrieve] |
| 10. | Sadou, F., Finkbeiner, S., Devys, D., and Greenberg, M. E. (1998) Cell 95, 55-66[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Sisodia, S. S. (1998) Cell 95, 1-4[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Khoshnan, A., Ko, J.,
and Patterson, P. H.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
1002-1007 |
| 13. |
Gutekunst, C. A., Li, S. H., Yi, H.,
Mulroy, J. S.,
Kuemmerle, S.,
Jones, R.,
Rye, D.,
Ferrante, R. J.,
Hersch, S. M.,
and Li, X. J.
(1999)
J. Neurosci.
19,
2522-2534 |
| 14. | Kuemmerle, S., Gutekunst, C. A., Klein, A. M., Li, X. J., Li, S. H., Beal, M. F., Hersch, S. M., and Ferrante, R. J. (1999) Ann. Neurol. 46, 842-849[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., and Wanker, E. E. (1997) Cell 90, 549-558[CrossRef][Medline] [Order article via Infotrieve] |
| 16. |
Scherzinger, E.,
Sittler, A.,
Schweiger, K.,
Heiser, V.,
Lurz, R.,
Hasenbank, R.,
Bates, G. P.,
Lehrach, H.,
and Wanker, E. E.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
4604-4609 |
| 17. | Kazantsev, A., Walker, H. A., Slepko, N., Bear, J. E., Preisinger, E., Steffan, J. S., Zhu, Y. Z., Gertlet, F. B., Housman, D. E., Marsh, J. L., and Thompson, L. M. (2002) Nat. Genet. 30, 367-376[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Peters, M. F., and Ross, C. A. (1999) Neurosci. Lett. 275, 129-132[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Peters, M. F.,
and Ross, C. A.
(2001)
J. Biol. Chem.
276,
3188-3194 |
| 20. | Fu, F.-N., Lomneth, R. B., Cai, S., and Singh, B. R. (1998) Biochemistry 37, 5267-5278[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Rivetti, C., Guthold, M., and Bustamante, C. (1999) EMBO J. 18, 4464-4475[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Fink, A. L. (1998) Curr. Biol. 3, 9-23 |
| 23. | Haris, P. (2000) Infrared Analysis of Peptides and Proteins: Principles and Applications , American Chemical Society, Washington, D. C. |
| 24. |
Heiser, V.,
Scherzinger, E.,
Boeddrich, A.,
Nordhoff, E.,
Lurz, R.,
Schugardt, N.,
Lehrach, H.,
and Wanker, E. E.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
6739-6744 |
| 25. | Altschuler, E. L., Hud, N. V., Mazrimas, J. A., and Rupp, B. (1997) J. Pept. Res. 50, 73-75[Medline] [Order article via Infotrieve] |
| 26. | Chen, S., Berthelier, V., Yang, W., and Wetzel, R. (2001) J. Mol. Biol. 311, 173-182[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Masino, L., Kelly, G., Leonard, K., Trottier, Y., and Pastore, A. (2002) FEBS Lett. 513, 267-272[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Harper, J. D., Wong, S. S., Lieber, C. M., and Lansbury, P. T., Jr. (1999) Biochemistry 38, 8972-8980[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Rochet, J. C., Conway, K. A., and Lansbury, P. T., Jr. (2000) Biochemistry 39, 10619-10626[CrossRef][Medline] [Order article via Infotrieve] |
| 30. |
Serio, T. R.,
Cashikar, A. G.,
Kowal, A. S.,
Sawicki, G. J.,
Moslehi, J. J.,
Serpell, L.,
Arnsdorf, M. F.,
and Lindquist, S. L.
(2000)
Science
289,
1317-1321 |
| 31. |
O'Nuallain, B.,
and Wetzel, R.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
1485-1490 |
| 32. | Klein, W. L., Krafft, G. A., and Finch, C. E. (2001) Trends Neurosci. 24, 219-224[CrossRef][Medline] [Order article via Infotrieve] |
| 33. |
Conway, K. A.,
Rochet, J.-C.,
Bieganski, R. M.,
and Lansbury Jr, P. T.
(2001)
Science
294,
1346-1349 |
| 34. | Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., and Stefani, M. (2002) Nature 416, 507-511[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Walsh, D. M., Klyubn, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Nature 416, 535-539[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
S. Alves, E. Regulier, I. Nascimento-Ferreira, R. Hassig, N. Dufour, A. Koeppen, A. L. Carvalho, S. Simoes, M. C. P. de Lima, E. Brouillet, et al. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease Hum. Mol. Genet., July 15, 2008; 17(14): 2071 - 2083. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takahashi, S. Kikuchi, S. Katada, Y. Nagai, M. Nishizawa, and O. Onodera Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic Hum. Mol. Genet., February 1, 2008; 17(3): 345 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ignatova, A. K. Thakur, R. Wetzel, and L. M. Gierasch In-cell Aggregation of a Polyglutamine-containing Chimera Is a Multistep Process Initiated by the Flanking Sequence J. Biol. Chem., December 14, 2007; 282(50): 36736 - 36743. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shao and M. I. Diamond Polyglutamine diseases: emerging concepts in pathogenesis and therapy Hum. Mol. Genet., October 15, 2007; 16(R2): R115 - R123. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stefani Generic Cell Dysfunction in Neurodegenerative Disorders: Role of Surfaces in Early Protein Misfolding, Aggregation, and Aggregate Cytotoxicity Neuroscientist, October 1, 2007; 13(5): 519 - 531. [Abstract] [PDF] |
||||
![]() |
S. Barton, R. Jacak, S. D. Khare, F. Ding, and N. V. Dokholyan The Length Dependence of the PolyQ-mediated Protein Aggregation J. Biol. Chem., August 31, 2007; 282(35): 25487 - 25492. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Takahashi, Y. Okamoto, H. A. Popiel, N. Fujikake, T. Toda, M. Kinjo, and Y. Nagai Detection of Polyglutamine Protein Oligomers in Cells by Fluorescence Correlation Spectroscopy J. Biol. Chem., August 17, 2007; 282(33): 24039 - 24048. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Necula, R. Kayed, S. Milton, and C. G. Glabe Small Molecule Inhibitors of Aggregation Indicate That Amyloid beta Oligomerization and Fibrillization Pathways Are Independent and Distinct J. Biol. Chem., April 6, 2007; 282(14): 10311 - 10324. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. Schiffer, S. A. Broadley, T. Hirschberger, P. Tavan, H. A. Kretzschmar, A. Giese, C. Haass, F. U. Hartl, and B. Schmid Identification of Anti-prion Compounds as Efficient Inhibitors of Polyglutamine Protein Aggregation in a Zebrafish Model J. Biol. Chem., March 23, 2007; 282(12): 9195 - 9203. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Li, E. S. Chevalier-Larsen, D. E. Merry, and M. I. Diamond Soluble Androgen Receptor Oligomers Underlie Pathology in a Mouse Model of Spinobulbar Muscular Atrophy J. Biol. Chem., February 2, 2007; 282(5): 3157 - 3164. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Slepko, A. M. Bhattacharyya, G. R. Jackson, J. S. Steffan, J. L. Marsh, L. M. Thompson, and R. Wetzel Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins PNAS, September 26, 2006; 103(39): 14367 - 14372. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Ehrnhoefer, M. Duennwald, P. Markovic, J. L. Wacker, S. Engemann, M. Roark, J. Legleiter, J. L. Marsh, L. M. Thompson, S. Lindquist, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models Hum. Mol. Genet., September 15, 2006; 15(18): 2743 - 2751. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bader, M. A. Seeliger, S. E. Kelly, L. L. Ilag, F. Meersman, A. Limones, B. F. Luisi, C. M. Dobson, and L. S. Itzhaki Folding and Fibril Formation of the Cell Cycle Protein Cks1 J. Biol. Chem., July 7, 2006; 281(27): 18816 - 18824. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Ellisdon, B. Thomas, and S. P. Bottomley The Two-stage Pathway of Ataxin-3 Fibrillogenesis Involves a Polyglutamine-independent Step J. Biol. Chem., June 23, 2006; 281(25): 16888 - 16896. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Matsumoto, S. Kim, and R. I. Morimoto Huntingtin and Mutant SOD1 Form Aggregate Structures with Distinct Molecular Properties in Human Cells J. Biol. Chem., February 17, 2006; 281(7): 4477 - 4485. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Berger, J. E. Davies, S. Luo, M. Y. Pasco, I. Majoul, C. J. O'Kane, and D. C. Rubinsztein Deleterious and protective properties of an aggregate-prone protein with a polyalanine expansion Hum. Mol. Genet., February 1, 2006; 15(3): 453 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Valera, M. Diaz-Hernandez, F. HernANdez, Z. Ortega, and J. J. Lucas The Ubiquitin-Proteasome System in Huntington's Disease Neuroscientist, December 1, 2005; 11(6): 583 - 594. [Abstract] [PDF] |
||||
![]() |
Q. Wang, D. D. Mosser, and J. Bag Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells Hum. Mol. Genet., December 1, 2005; 14(23): 3673 - 3684. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Diaz-Hernandez, J. Torres-Peraza, A. Salvatori-Abarca, M. A. Moran, P. Gomez-Ramos, J. Alberch, and J. J. Lucas Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease J. Neurosci., October 19, 2005; 25(42): 9773 - 9781. [Abstract] [Full Text] [PDF] |
||||
![]() |
|